Nicox is an international ophthalmology company that is dedicated to developing innovative therapeutics to support vision and improve ocular health. Their portfolio includes a range of products and product candidates designed to target various eye diseases. The lead program in their ophthalmic pipeline is NCX 470, which is currently in Phase 3 clinical development with a focus on treating glaucoma.

They also have NCX 1728, a candidate under preclinical evaluation for retinal conditions, and NCX 4251, a product candidate for dry eye disease that is at a development stage and has a licensed partner for the Chinese market. In addition, Nicox has two products already commercialized in the U. S.

: VYZULTA® for open-angle glaucoma and ZERVIATE® for ocular allergic conjunctivitis. Nicox is committed to discovering and developing novel ophthalmic therapeutics for eye diseases, ensuring the highest standards of eye care for patients worldwide. They have a highly experienced leadership team with expertise covering various aspects of the pharmaceutical industry, including research, clinical development, finance, and business development.

Nicox is focused on making a meaningful impact in the field of ocular health through their innovative solutions